3Wigley M, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum, 2005, 52: 2125-2132.
4Winslow TM, Ossipow MA, Fazio GP, et al. Five year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J, 1995, 129:510-515.
5Li EK, Tam LS. Pulmonary hypertension in systemic lupus erythematosus: circulation association and survival in 18 patients. J Rheumatol, 1999, 26: 1923-1929.
6Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum, 2003, 48: 516-522.
7Humbert M, Barst R J, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: breathe-2. Eur Respir J, 2004, 24: 353-359.
8David B, Steve H, Gregory S. Medical therapy for pulmonary arterial hypertension. Chest, 2004, 126: 35-62.
9De Papa N, Conforti G, Gambini D, et al. Characterization of the endothelial surface proteins by antiendothelial antibodies in primary and secondary autoimmune vasculitis. Clin Immunol Immunopathol, 1994, 70: 211-216.
10Giaid A. Nitric oxide and endothelin-1 in pulmonary hypertension. Chest, 1998, 114: 208-212.
